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Background: YKL-40, a chitinase-like cartilage glycoprotein, has recently shown its
potential as a marker for sarcoidosis.
Methods: This study aimed to assess whether YKL-40 at presentation may predict the
course of sarcoidosis over a 4-year follow-up period and to investigate whether
polymorphisms in the chitinase 3-like 1 (CHI3L1) gene might influence serum YKL-40
levels in sarcoidosis patients (n ¼ 63) and controls (n ¼ 333).
Results: Patients had significantly higher (mean, 95% CI) serum YKL-40 levels (181.3 ng/ml,
50.7–648.1) compared to controls (36.6 ng/ml, po0.0001. Serum YKL-40 was elevated in
79% of the patients and was inversely correlated with DLco at presentation (r2 ¼ 0:27,
p ¼ 0:03), but not after 2–4 years of follow-up (r2 ¼ 0:16, p ¼ 0:27). Serum YKL-40 levels
in controls were dependent on the CHI3L1 329 G/A polymorphism (mean, 95% CI): GG
(n ¼ 213) 48.3ng/ml, 41.7–56.0; GA (n ¼ 101) 31.2ng/ml, 26.6–36.3; AA (n ¼ 17) 17.8ng/ml,
13.6–23.4, po0.0001. In patients, this effect was not observed.
Conclusions: YKL-40 may be used as a sarcoidosis disease marker, but it is unsuitable as a
marker to predict the course of the disease. The CHI3L1 329 G/A polymorphism
contributes to inter-individual variations of YKL-40 levels, but does not influence
sarcoidosis disease susceptibility or severity.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Sarcoidosis is a systemic disease of unknown cause and is
characterized by the presence of noncaseating granulomas
in one or multiple organs.1 The majority of patients have
pulmonary involvement and although most undergo sponta-
neous remission, about 10–15% of the cases progress
insidiously towards pulmonary fibrosis.2 Fibrosis of the lung
parenchyma is marked by excessive extra-cellular matrix
deposition which can lead to end-stage fibrosis with
honeycombing of the lungs. This sequela is associated with
loss of lung capacity and has a poor prognosis with high
mortality.3
It is challenging to find reliable sarcoidosis disease
markers that are capable of predicting the course of the
disease. The human cartilage glycoprotein-39, or YKL-40 (its
name derived from the first three N-terminal amino acids
and from its molecular weight of 40 kDa) has recently shown
its potential merit as a marker for sarcoidosis.4 Beside the
reported overall increase of serum YKL-40 levels in
sarcoidosis patients compared to controls, pulmonary
carbon monoxide diffusion (DLco) was found to be inversely
correlated with serum YKL-40 levels.4 The authors of this
study concluded that YKL-40 may serve as a marker for
disease activity as well as fibrosis in sarcoidosis patients.
In addition to sarcoidosis, serum YKL-40 is also elevated in
systemic sclerosis,5,6 rheumatoid arthritis,7–9 liver fibro-
sis,10,11 inflammatory bowel disease,12 and type 2 dia-
betes.13 Moreover, elevated YKL-40 has been reported to
predict shorter survival in cancer patients.14–19
YKL-40 is a member of the chitinase family and is secreted
by articular chondrocytes and synovial cells20 as well as by
disease-associated cells including cancer21,22 and inflamma-
tory cells.4,23,24 Unlike its other family members, YKL-40
does not exert chitinase activity.20 Instead, a single amino
acid substitution causes YKL-40 to replace its potential
chitinase property to the ability to bind lectin.25 Although
its precise function has not yet been elucidated, the
biological properties of YKL-40 suggest that it plays a role
in tissue inflammation, remodeling, and the development of
fibrosis.26–28 In fact, in vitro studies by Recklies et al.29 have
shown that YKL-40 is a potent growth factor for connective
tissue cells including human fibroblasts.
Another chitinase that has been studied as a potential
marker for sarcoidosis is chitotriosidase.30 Contrary to YKL-
40, this protein does exert chitinase activity and is also
highly expressed by activated macrophages.25 Chitotriosi-
dase has even shown to be higher in advanced radiographic
stages of the sarcoidosis.30 The precise role of chitotriosi-
dase in the pathogenesis of sarcoidosis has, like YKL-40, not
yet been identified.
Single nucleotide polymorphisms (SNPs) of genes that are
involved in the pathogenesis of sarcoidosis have shown to
contribute to the vastly different patterns with which this
disease can evolve.31 SNPs may alter the nature of a protein
and is reflected by altered physiologic properties or changed
expression levels. Functional polymorphisms present in
proteins which are used as disease markers may complicate
the interpretation of differential protein levels in both
healthy and affected individuals. In the ACE gene, for
instance, an insertion/deletion (I/D) polymorphism in intron
16 is known to exhibit gross differences of baselineexpression levels based on the genotype of the coding
gene.32 As a consequence, the precision needed to
differentiate between normal and deviating levels may be
compromised.33
The YKL-40 coding chitinase 3-like 1 (CHI3L1) gene also
bears a large number of polymorphic sites, some of which
are potentially functional. The aim of this study was to
investigate whether SNPs in the CHI3L1 gene may influence
serum YKL-40 levels in Dutch Caucasian sarcoidosis patients
and healthy controls. The biallelic polymorphisms which we
evaluated included two that are present in the promoter
region, three in different intron/exon boundaries and one
SNP in exon 5 that causes an amino acid substitution
(Arg145Gly).
We also tested the hypothesis by Johansen et al.4 that
YKL-40 levels may predict the course of pulmonary
sarcoidosis by comparing the YKL-40 levels at presentation
with radiographic evolution and pulmonary function tests
over a 4-year follow-up period.Methods
Healthy volunteers and patients
Venous blood samples were obtained from 333 ostensibly
healthy employees of the St Antonius Hospital; 214 women
(39712.0 years) and 119 men (42710.2 years). By complet-
ing a questionnaire, relevant background information was
provided by these volunteers which included medication,
ethnicity, and hereditary diseases. The over-representation
of women who participated in this study is explained by the
predominantly female workforce at this hospital. Fifty-five
individuals (33 women and 22 men) smoked for at least
5 pack-years. Ethnicity of both parents was used as the
criterion for assuming Dutch Caucasian ethnicity of the
subject. Exclusion criteria included known pulmonary
disease and non-Dutch Caucasian ethnicity. The medical
ethical committee of this hospital approved the study
conducted and all subjects gave formal written consent.
Seventy-five unrelated Dutch Caucasian sarcoidosis pa-
tients (44 males/31 females; age at diagnosis (years)7SD/
range: 39711.2 years/17–71) were included in this retro-
spective study. The diagnosis of sarcoidosis was established
in 50 patients when clinical findings were supported by
histological evidence and after exclusion of other known
causes of granulomatosis in accordance with the consensus
of the ATS/ERS/WASOG statement on sarcoidosis.34
Chest radiographs were assessed to determine disease
severity using standard radiographic staging for sarcoidosis,
classified according to the Scadding criteria.34 One patient
presented with radiographic stage 0, 20 patients presented
with stage I, 11 patients presented with stage II, 15 patients
presented with stage III, and three patients presented with
stage IV disease. In 25 patients, the diagnosis was made
without biopsy proof because these patients presented with
the classic symptoms of Lo¨fgren’s syndrome, namely fever,
erythema nodosum, arthralgia, and bilateral hilar lympha-
denopathy.
No prior treatment for sarcoidosis was given prior to
presentation. After presentation, individuals who were
treated with corticosteroids for at least 3 months during
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Primer Consensus Product size
(bp)
329 (G/A) rs10399931 50-CGG CTG AGT CAC ATC TCC 50-CAG GCC CTG TAC TTC CTT 261
Promoter G/A (forward) TA (reverse)
247 (C/T) rs10399805 50- AGA GGA GGG TTG AGA AAC 50-TGC TGA AGA TGC AAA 220
Promoter CG/A (reverse) GGT AGA G (forward)
48 (T/A) rs7515776 50-ATC TGG GCT AGC CAA GGT 50-AGA GAA ATC CAG GAT 247
Intron1/exon1 TAA T/A (forward) GAG ACC (reverse)
1219 (C/T) rs1538372 50-CCT GAA GGA GAA GTC TGG G 50-TAG CGT ATT CAT CCC 265
Intron2/exon3 G/A (reverse) CTG CA (forward)
2117 (C/G) rs2071579 50-GAA CAT CCA TAC AGT GGA 50-TAA CCC AGC CTC TCA 264
Intron4/exon4 TG G/C (reverse) CCC AA (forward)
2950 (G/A) rs880633 50-GGT GGT AAA ATG CTG TTT 50-GCA TGC TAC AGG GCT 171
Exon 5 GTC TC C/T (reverse) GAT TTT (forward)
The SNP loci were identified using accession numbers according to the SNP database at: http://www.ncbi.nlm.nih.gov/entrez/
query.fcgi?db=snp (accessed July 2005).
CHI3L1 gene polymorphism and serum levels of YKL-40 1565the 4-year follow-up period, were considered as having
received treatment (n ¼ 28). No other treatment regimens
had been used in the study group.
Radiographic evolution over a 4-year follow-up period was
categorized as follows: acute/self-remitting (normalization
or improvement towards stage I) (n ¼ 25), chronic (persis-
tent stage II/III or progression towards this stage) (n ¼ 16),
and fibrosis (stable stage IV or progressive towards this
stage) (n ¼ 9), and patients with Lo¨fgren’s syndrome
(n ¼ 25). Except for one, all patients with Lo¨fgren’s disease
had received radiographic follow-up. These patients had
normalized chest radiography after 2 or 4 years following
presentation, except for one patient, who remained at
radiographic stage I after 4 years.
Pulmonary function tests were performed at presentation
and upon 2, and 4 years following diagnosis. Vital capacity
(inspiratory) (VC), forced expiratory volume in 1 s (FEV1),
and carbon monoxide diffusing lung capacity (DLco) were
used to assess the presence of lung function impairment at
presentation and follow-up of disease. All lung function
parameters are expressed as percent predicted values. VC
and FEV1 were calculated from volumes in liters and
adjusted to BTPS (body temperature, ambient pressure,
saturated with water vapor) in accordance with the ERS
recommendations.35
The medical ethical committee of the St. Antonius
Hospital approved the study conducted and all subjects
gave formal written consent.
Serum YKL-40 measurements
Serum YKL-40 was measured with an enzyme-linked im-
munosorbent assay kit (Metra YKL-40, Quidel Corporation,
San Diego, CA, USA), in accordance with the manufacturer’s
instructions.36 All samples were run in duplicate and mean
values were used for analysis. The mean intra-assay
coefficient of variance (CV) was calculated from two
control samples (low: 40 ng/l and high: 150 ng/l) that wereboth measured in duplicate on 5 different days. The CV
was 3.5%.
Serum YKL-40 levels were measured in patients only at
presentation of sarcoidosis.
Genotyping
Biallelic SNPs were determined using sequence-specific
primers) and polymerase chain reaction (PCR).
The identification numbers of the SNP loci and the
sequences of SNP-specific primers with their complementary
consensus primers are shown in Table 1. The PCR conditions
were as previously described.37 The final primer concentra-
tions used were 7.6 ng/ml. DNA was available from 63
patients.
Statistical analysis
The statistical evaluation of our data was performed using
SPSS 11 (SPSS Inc., Chicago, IL, USA) and Graphpad Prism v. 4
(Graphpad Software, Inc., San Diego, CA, USA) software
packages. Statistical analyses of SNP and haplotype fre-
quency distributions were performed using chi-square
contingency table analysis with the appropriate number
of degrees of freedom. Fisher’s exact test was used if
expected cell frequencies were lower than 5. Adjustment
for multiple tests was made by multiplying the p-value by
the number of SNPs being investigated (Bonferroni method).
Genotype frequencies were tested for Hardy–Weinberg
equilibrium. Haplotypes were determined using Phase,
version 2 (Mac OS X).38,39
YKL-40 values were ln-transformed before analysis, since
these were ln-normal distributed; antilog geometric mean
values are denoted as mean. Analysis of variance was
performed and the portion of the serum YKL-40 level
variance, explained by the CHI3L1 genotype and other
factors, was estimated. Fixed factors in the ANOVA model
were gender, smoking history, and the CHI3L1 genotype.
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Figure 1 Receiver operating characteristic curve of serum
YKL-40 with 333 healthy controls and 75 sarcoidosis patients.
Figure 2 Scatter plot of serum YKL-40 levels (ng/ml) in
sarcoidosis patients (n ¼ 62) with diffusion capacity (DLco)
below and equal/above the mean (85%). Horizontal bars in
scatter represent mean values. Y-axis represents log-trans-
formed values. Student’s t-test: p ¼ 0:004.
A. Kruit et al.1566Age was included as a covariate. The ANOVA was followed by
the appropriate post-testing for comparisons between
groups. Correlation between variables was assessed with
Spearman’s rho.
The sensitivity and the specificity were established using
the receiver operating characteristic (ROC) curve by
plotting the sensitivity against the reverse specificity
(1specificity) at each value.
Statistical significance was denoted by a value of po0.05
for all tests performed.Results
Serum YKL-40 levels in controls
Mean (median) serum YKL-40 in controls was 36.6 (37.3) ng/
ml. The calculated reference range (mean71.96 SD) was:
11.9–110.0 ng/ml.
Age correlated with YKL-40 levels (r2 ¼ 0:23, po0.0001)
and explained 5% of the variation. Smoking history or gender
did not significantly influence serum YKL-40 levels (data not
shown).Serum YKL-40 levels in patients
Sarcoidosis patients had significantly higher (mean (med-
ian), 95% CI) serum YKL-40 levels (181.3 (210.0) ng/ml,
50.7–648.1) compared to controls, po0.0001. Based on the
reference interval of controls, 59 sarcoidosis patients (79%)
showed serum YKL-40 levels that exceeded the upper
reference limit.
An ROC curve revealed that at the value of 72.0 ng/ml,
serum YKL-40 had a sensitivity of 90% and a specificity of
72%. The area under the curve was 0.953 (Fig. 1).YKL-40 levels and clinical parameters in sarcoidosis
patients
Radiographic staging at presentation or radiographic evolu-
tion were not associated with YKL-40 levels (data not
shown). Since treatment in a number of patients (n ¼ 28)
was not given at the time of presentation, the influence of
treatment on serum YKL-40 levels could not be determined
for that time point. However, YKL-40 levels at presentation
(242.3 ng/ml, 95% CI: 195.7–289.0) were not different
between those patients who received subsequent treatment
within the 4-year follow-up period and those who did not
(232.6 ng/ml, 95% CI: 184.3–280.9).
Serum YKL-40 showed an inverse correlation with DLco (%)
at presentation (r2 ¼ 0:27, p ¼ 0:03), but not with DLco
measured at 2–4 years (r2 ¼ 0:16, p ¼ 0:27). Sarcoidosis
patients who had DLco levels below the mean (85%) had
significantly higher mean serum YKL-40 levels than those
with DLco values equal to or above the mean: 259.8 ng/ml,
95% CI: 200.3–317.3 versus 170.7 ng/ml, 95% CI: 134.3–
210.6, p ¼ 0:004 (Fig. 2).
Neither FEV1 nor VC (both measured at presentation or
after 2–4 years) correlated with serum YKL-40 levels (data
not shown).CHI3L1 single nucleotide polymorphisms
Table 2 summarizes the results of CHI3L1 genotype and
allele carrier frequencies in the Dutch sarcoidosis patients
and controls. No deviation from Hardy–Weinberg equilibrium
was observed for any of the groups studied. No differences
were found for genotype, allele or allele carrier frequencies
between sarcoidosis patients and controls. None of the
polymorphisms were associated with any of the clinical
parameters including lung function and radiographic staging
(data not shown).
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CHI3L1 gene polymorphism and serum levels of YKL-40 1567Four major haplotypes with six polymorphic sites in the
CHI3L1 gene were established (Table 3). There was no
difference in haplotype frequencies between sarcoidosis
patients and controls.Table 2 CHI3L1 allele carrier and genotype frequencies







329 (G/A) G 0.94 (314) 0.97 (61)
A 0.35 (118) 0.29 (18)
GG 0.65 (215) 0.71 (45)
AG 0.30 (101) 0.25 (16)
AA 0.05 (17) 0.03 (2)
247 (C/T) C 0.98 (328) 0.98 (62)
T 0.24 (79) 0.25 (16)
CC 0.76 (254) 0.74 (47)
CT 0.22 (74) 0.24 (15)
TT 0.02 (5) 0.02 (1)
48 (T/A) T 0.98 (328) 0.98 (62)
A 0.24 (79) 0.25 (16)
TT 0.76 (254) 0.74 (47)
TA 0.22 (74) 0.24 (15)
AA 0.02 (5) 0.02 (1)
1219 (C/T) C 0.94 (314) 0.98 (62)
T 0.47 (157) 0.44 (28)
CC 0.53 (176) 0.56 (35)
CT 0.41 (138) 0.43 (27)
TT 0.06 (19) 0.02 (1)
2117 (C/G) C 0.81 (269) 0.79 (50)
G 0.70 (233) 0.62 (39)
CC 0.30 (100) 0.38 (24)
CG 0.51 (169) 0.41 (26)
GG 0.19 (64) 0.20 (13)
2950 (G/A) G 0.83 (277) 0.79 (50)
A 0.69 (230) 0.62 (39)
GG 0.31 (103) 0.38 (24)
GA 0.52 (174) 0.41 (26)
AA 0.17 (56) 0.20 (13)
Table 3 CHI3L1 haplotype frequencies in sarcoidosis patients a
Haplotype 329 (G/A) 247 (C/T) 48 (T/A) 1219 (C
1 G C T C
2 A C T T
3 G T A C
4 G C T T
5 G C T C
6 A C T C
7–10 — — — —
One of each haplotype occurred no more than 3 times.Association between genetic variants of CHI3L1 and
serum YKL-40 levels in controls and sarcoidosis
patients
Each SNP in the CHI3L1 gene was analyzed for association
with serum YKL-40 levels. All six polymorphic sites were
found to influence serum YKL-40 levels in a gene-dose-
dependent manner. Figure 3A illustrates the effect of SNP
329 G/A on serum YKL-40 levels in healthy controls. To test
whether the variation in YKL-40 levels was influenced
independently by the individual SNPs or by linkage dis-
equilibrium between them, a multivariate analysis was
performed. In this model, which was adapted from the
method used by Zhu et al.,40 the SNP that explained most of
the variation of serum YKL-40 levels was selected as a
covariate to identify the influence of the remaining SNPs
(analyzed separately). The 329 G/A polymorphism showed
the highest variance: 23%, po0.0001). Also, age was
included as a covariate and gender and smoking history
were included as fixed factors. The analysis revealed that
the correction of serum YKL-40 levels by the 329 G/A
polymorphism negated the influence of the other poly-
morphisms on serum YKL-40 levels (Table 4). The isolated
effect of the 329 G/A SNP was also illustrated by
determining haplotype-specific serum YKL-40 levels. When
heterozygous carriers of either of the haplotypes in
combination with haplotype 1 were compared with each
other in terms of (mean) serum YKL-40 levels, the only
significant differences were those observed between haplo-
types that differed from the 329 allele: haplotype carrier
1+1 (43.8 ng/ml) versus 1+2 (28.8 ng/ml), po0.0001; hap-
lotype carrier 1+2 (28.8 ng/ml) versus 1+3 (49.4 ng/ml),
po0.0001; haplotype carrier 1+2 (28.8 ng/ml) versus 1+4
(44.7 ng/ml), po0.05; haplotype carrier 1+2 (28.8 ng/ml)
versus 1+5 (60.3 ng/ml), po0.01; haplotype carrier 1+5
(60.3 ng/ml) versus 1+6 (22.3 ng/ml), po0.05.
The 329 G/A polymorphism did not appear to signifi-
cantly influence serum YKL-40 levels in sarcoidosis patients
(Fig. 3B) despite the trend towards lower mean values
associated with the presence of the A allele: genotype AG
(153.2 ng/ml) compared to GG (192.7 ng/ml), p ¼ 0:16, nor
did correcting the effect of the 329 G/A SNP for smoking,
gender, and age in a multivariate analysis reveal a genotype-
dependent influence on serum YKL-40 levels (data not
shown). Age correlated significantly with serum YKL-40 in and controls.






C G 0.53 0.58
G A 0.17 0.13
G A 0.12 0.13
G A 0.09 0.10
G A 0.02 0.03
C G 0.02 0.01
— — 0.05 0.02
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Figure 3 (A) Scatter plot illustrating the association between the 329 G/A polymorphism in the CHI3L1 gene and serum YKL-40
levels in healthy controls (n ¼ 333). Horizontal bars in scatters represent mean values. Y-axis represents log-transformed values.
ANOVA: po0.0001. (B) Scatter plot illustrating the association between the 329 G/A polymorphism in the CHI3L1 gene and serum
YKL-40 levels in sarcoidosis patients (n ¼ 63). Horizontal bars in scatters represent mean values. Y-axis represents log-transformed
values. ANOVA: p ¼ 0:29.
Table 4 CHI3L1 gene polymorphisms and the influence on serum YKL-40 levels in controls.
Polymorphism Genotype-specific YKL-40 levels (ng/ml) (mean, 95% CI) Differences between
genotype-specific YKL-
40 serum levels
329 (G/A) GG (n ¼ 213) 48.3, 41.7–56.0 po0.00001
GA (n ¼ 101) 31.2, 26.6–36.3
AA (n ¼ 17) 17.8, 13.6–23.4
247 (C/T) CC (n ¼ 254) 39.4, 34.2–45.5 p ¼ 0:25y
CT (n ¼ 72) 43.1, 36.4–51.0
TT (n ¼ 5) 50.1, 32.0–78.4
48 (T/A) TT (n ¼ 252) 39.4, 34.1–45.4 p ¼ 0:27y
TA (n ¼ 72) 43.1, 36.4–51.2
AA (n ¼ 7) 47.7, 31.6–72.1
1219 (C/T) CC (n ¼ 176) 40.5, 34.7–47.3 p ¼ 0:07y
CT (n ¼ 138) 40.0, 34.2–46.8
TT (n ¼ 19) 42.2, 32.0–55.5
2117 (C/G) CC (n ¼ 100) 36.9, 31.2–43.6 p ¼ 0:14y
CG (n ¼ 168) 41.0, 35.5–47.5
GG (n ¼ 63) 43.1, 35.9–51.8
2950 (G/A) GG (n ¼ 103) 39.5, 34.2–45.6 p ¼ 0:43y
GA (n ¼ 173) 42.4, 35.7–50.6
AA (n ¼ 55) 49.2, 35.3–68.6
Corrected for smoking history, gender, and age.
ySNP 329 G/A was used as a covariate to determine the effects of the remaining five SNPs on serum YKL-40 levels. Smoking history,
gender and age were also included as fixed factor or covariate. Mean YKL-40 and 95% CI were calculated from log-transformed data.
A. Kruit et al.1568
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CHI3L1 gene polymorphism and serum levels of YKL-40 1569similar pattern as that which was observed in the control
population (r2 ¼ 0:24, p ¼ 0:04). No association was found
between the remaining five polymorphisms and serum YKL-
40 levels in sarcoidosis patients (data not shown).
The observed association between DLco and serum YKL-40
levels was not attributed to the 329 G/A genotype
distribution between patients below and equal/above the
mean DLco (85%) (data not shown).
Age and genotype-specific reference intervals
In order to calculate the expected serum YKL-40 levels of an
individual that is corrected for age and the 329 G/A
genotype, the following formulas were deduced from the
multivariate analysis:329 GG genotype: ln (serum YKL-40 (ng/ml))
¼ 3.348+0.012 age (years)70.944,
329 AG genotype: ln (serum YKL-40 (ng/ml))
¼ 2.916+0.012 age (years)70.944,
329 AA genotype: ln (serum YKL-40 (ng/ml))
¼ 2.362+0.012 age (years)70.944.When the expected serum YKL-40 levels were calculated
for the sarcoidosis patients, the number of patients with
either elevated or normal serum YKL-40 levels remained
unchanged.
Discussion
This study supports the merits of serum YKL-40 as a disease
marker for sarcoidosis, as previously shown by Johansen
et al.4 Serum YKL-40 levels were found to be elevated in 79%
of the sarcoidosis patients. However, the low specificity and
the previously described elevations of YKL-40 associated
with various other diseases5–12 may limit the use of YKL-40
as a diagnostic marker for sarcoidosis.
Serum YKL-40 levels were found to increase with age,
although the extent to which serum YKL-40 was elevated in
sarcoidosis patients was too high to allow age to influence
the accuracy of serum YKL-40 as a sarcoidosis marker.
The inverse correlation between serum YKL-40 levels and
DLco seemed to suggest that YKL-40 is related to the
development of pulmonary fibrosis. This notion was also
reported by Johansen et al.4 and is well supported by the
fact that YKL-40 is a strong growth factor for human
fibroblasts.29 However, since the development of pulmonary
fibrosis is usually irreversible,3 the lack of correlation
between DLco measured at later time points during follow-
up and serum YKL-40 levels measured at presentation does
therefore suggest against the presence of fibrosis. Vascular
involvement in pulmonary sarcoidosis is often seen41 and is,
like fibrosis, often reflected by a decreased DLco.42 The
observed correlation between YKL-40 and DLco may there-
fore be attributed to events that remain yet to be identified.
Contrary to what Johansen et al.4 have described, YKL-40
levels above the median were not associated with decreased
DLco values. Instead, sarcoidosis patients with DLco values
below the mean had higher YKL-40 levels. An observation
similar to ours has been reported in systemic sclerosis
patients with pulmonary fibrosis by chest X-ray. In thisreport, patients with decreased DLco showed higher serum
YKL-40 levels in serum.5 Although our findings emerged from
assessing a larger group of patients of whom DLco as well as
YKL-40 data were available (n ¼ 44 versus n ¼ 27), even
larger groups should be used to resolve the inconsistent
findings between Johansen’s and our study.
This study is the first to describe a genotypic influence of
the CHI3L1 329 G/A polymorphism on serum YKL-40 levels
in healthy individuals. This polymorphism was shown to
explain as much as 23% of the variation in serum YKL-40
levels. In the sarcoidosis patients, the genotype-dependent
effect of the 329 G/A polymorphism was not observed.
Possibly, in a disease state, pathologic factors involved in
sarcoidosis which contribute to an increase of YKL-40 levels
may over-rule the variance attributed to the 329 G/A
polymorphism in CHL3L2. Just as what was argued for age,
there may not be a diagnostic merit in correcting serum YKL-
40 levels for the 329 G/A genotype.
To test the hypothesis that the 329 G/A genotype might
predispose to pulmonary fibrosis, significantly more patients
with fibrotic involvement as well as complete lung function,
radiographic data, and genotype are required.
Using an online tool to check for functional motifs at
position 329 did not reveal any changes in the motif found
for the wild-type nucleotide (http://motif.genome.jp/).
The actual position of the SNP is therefore unlikely to be the
quantitative trait locus (QTL) itself. Instead, it may be in
linkage with another, yet to be identified QTL. Like ACE, in
which the I/D polymorphism explains as much as 50% of the
variance of ACE activity through linkage with the actual
QTL,32,43 additional sequencing of the promoter region of
the CHI3L1 gene may indicate a site that is responsible for
an even higher variation of YKL-40 levels.Conclusion
This study shows that YKL-40 can be used as a disease
marker for sarcoidosis with the stipulation that other
diseases associated with elevated serum YKL-40 levels can
be excluded upon assessment and during follow-up. Serum
YKL-40 levels could not predict the course of pulmonary
disease phenotypes according to radiographic evolution over
a 4-year follow-up period. YKL-40 may be a useful marker in
combination with clinical parameters such as chest X-ray
and lung function and could aid in the follow-up monitoring
of disease activity. Furthermore, we delivered in vivo
evidence that the CHI3L1 329 G/A polymorphism con-
tributes to inter-individual variations of YKL-40 levels.
However, the CHI3L1 329 G/A polymorphism does not
seem to influence sarcoidosis disease susceptibility or
severity.
The observed influence of CHI3L1 329 G/A on serum
YKL-40 levels may also be of interest for investigations
involving YKL-40 in other diseases.Acknowledgements
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